6/27/2025

Janusmed sex and gender

Janusmed sex and gender – Methotrexate – high dose

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C! C!
C! C!

Methotrexate – high dose

Methotrexate – high dose

Class : C!

Show all info

Print

Contact us

  1. Gupta S, Teachey DT, Chen Z, Rabin KR, Dunsmore KP, Larsen EC et al. Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. Cancer. 2022;128(9):1863-1870.

  2. Pui CH, Boyett JM, Relling MV, Harrison PL, Rivera GK, Behm FG et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol. 1999;17(3):818-24.

  3. Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.

  4. Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood. 1998;92(10):3569-77.

  5. Rau T, Erney B, Göres R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther. 2006;80(5):468-76.

  6. Grželj J, Marovt M, Marko PB, Mlinarič-Raščan I, Gmeiner T, Šmid A. Polymorphism in Gene for ABCC2 Transporter Predicts Methotrexate Drug Survival in Patients with Psoriasis. Medicina (Kaunas). 2021;57(10):.

  7. Mitruk S, Avihingsanon A, and Punyawudho B. Polymorphisms of ABCC2, ABCC4, ABCC10 and SLC22A6 in Thai HIV - infected patients. Chulalongkorn Medical Journal. 2014;58(6):599-611.

  8. Hann I, Vora A, Harrison G, Harrison C, Eden O, Hill F et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol. 2001;113(1):103-14.

  9. Ishii E, Eguchi H, Matsuzaki A, Koga H, Yanai F, Kuroda H et al. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors. Med Pediatr Oncol. 2001;37(1):10-9.

  10. Ferrari S, Palmerini E, Staals E, Abate ME, Longhi A, Cesari M et al. Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma. J Chemother. 2009;21(2):205-10.

  11. Waber DP, Tarbell NJ, Kahn CM, Gelber RD, Sallan SE. The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol. 1992;10(5):810-7.

  12. Methotrexate Ebewe (metotrexat). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2023-07-24, cited 2024-03-17]

  1. Gupta S, Teachey DT, Chen Z, Rabin KR, Dunsmore KP, Larsen EC et al. Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. Cancer. 2022;128(9):1863-1870.
  2. Pui CH, Boyett JM, Relling MV, Harrison PL, Rivera GK, Behm FG et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol. 1999;17(3):818-24.
  3. Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.
  4. Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood. 1998;92(10):3569-77.
  5. Rau T, Erney B, Göres R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther. 2006;80(5):468-76.
  6. Grželj J, Marovt M, Marko PB, Mlinarič-Raščan I, Gmeiner T, Šmid A. Polymorphism in Gene for ABCC2 Transporter Predicts Methotrexate Drug Survival in Patients with Psoriasis. Medicina (Kaunas). 2021;57(10):.
  7. Mitruk S, Avihingsanon A, and Punyawudho B. Polymorphisms of ABCC2, ABCC4, ABCC10 and SLC22A6 in Thai HIV - infected patients. Chulalongkorn Medical Journal. 2014;58(6):599-611.
  8. Hann I, Vora A, Harrison G, Harrison C, Eden O, Hill F et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol. 2001;113(1):103-14.
  9. Ishii E, Eguchi H, Matsuzaki A, Koga H, Yanai F, Kuroda H et al. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors. Med Pediatr Oncol. 2001;37(1):10-9.
  10. Ferrari S, Palmerini E, Staals E, Abate ME, Longhi A, Cesari M et al. Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma. J Chemother. 2009;21(2):205-10.
  11. Waber DP, Tarbell NJ, Kahn CM, Gelber RD, Sallan SE. The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol. 1992;10(5):810-7.
  12. Methotrexate Ebewe (metotrexat). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2023-07-24, cited 2024-03-17]